Press Release

AATD (Alpha-1 Antitrypsin Deficiency) Augmentation Therapy Market 2019 Demand, Industry Size

AATD (Alpha-1 Antitrypsin Deficiency) Augmentation Therapy Market 2019 | Worldwide Trend, Analysis by Top Leading Player and Forecast Till 2026

The estimated rise in market value from its 2017 value of US$ 1115.5 Mn implies that the market will exhibit a CAGR of 5.9% in the foreacast period. Fortune Business Insights expects that factors such as regulatory approvals and improvements in augmentation therapies will drive the market in this period.

The Global AATD (Alpha-1 Antitrypsin Deficiency) Augmentation Therapy Market has been supported by late FDA endorsement for Prolastin-C. According to a report published by Fortune Business Insights, titled “AATD Augmentation Therapy: Global Analysis, Insights and Forecast, 2019-2026”, the market will be valued at US$ 1959.8 Mn by the end of 2026.

KEY PLAYERS COVERED

Some of the major companies that are present in the global alpha-1 antitrypsin deficiency Therapy market are Grifols, CSL, Baxter, Kamada, Takeda, Abeona Therapeutics.

Some of the major companies that are present in the Global Alpha-1 Antitrypsin Deficiency Therapy Market are;

  • Grifols S.A.
  • CSL Limited
  • Baxter
  • Kamada Ltd.
  • Takeda Pharmaceutical Company Limited
  • Abeona Therapeutics Inc., and other players.

Browse Complete Report [email protected] https://www.fortunebusinessinsights.com/industry-reports/aatd-augmentation-therapy-market-100169

Segmentation:

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Stores

By Route of Administration

  • Oral
  • Injection
  • Inhalation

By Drug Class

  • Alpha-1 proteinase inhibitor
  • Bronchodilators
  • Steroids
  • Antibiotics

North America to Dominate the Global Market

The growth in global alpha-1 antitrypsin deficiency treatment market is being driven by the emerging guideline for the treatment and diagnosis of alpha-1 antitrypsin deficiency treatment, potential pipeline products and rising awareness of alpha-1 antitrypsin deficiency. Furthermore, the rising prevalence of alpha-1 antitrypsin deficiency is expected to boost the global alpha-1 antitrypsin deficiency treatment market in the forecast period.

More Trending Topics From Fortune Business [email protected]

Diabetes Treatment Devices Market Size, Share & Growth Report 2026

Defibrillator Market Size Growth & Industry Dynamics 2026

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Tags

Dale Martinez

Dale possesses an engineering degree in Electronics from the Georgia Institute of Technology. She is the sole contributor at the Healthcare IT column. Before opting to write, Dale worked at major firms such as Microsoft, Amazon, GE, Raytheon, and so on. She possesses vast knowledge about a variety of fields like IT, IoT, Telecommunications, Health Dialysis, photovoltaic, and many others. Dale is also a ballet dancer.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close